Recruitment

Recruitment Status
Withdrawn
Estimated Enrollment
24

Inclusion Criterias

Age 18 years and older
Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic agents, etc) for at least 4 weeks
Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks
...
Age 18 years and older
Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic agents, etc) for at least 4 weeks
Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks
Male or female with diagnosis of psoriasis
Fitzpatrick Skin Types I-VI
Psoriasis involvement of 5-15% BSA

Exclusion Criterias

Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
Any suspicion that the psoriasis is of the photosensitive variant.
Any medical condition that could be aggravated or may cause extreme discomfort during the study period.
Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
Any suspicion that the psoriasis is of the photosensitive variant.
Any medical condition that could be aggravated or may cause extreme discomfort during the study period.

Summary

Conditions
Psoriasis
Type
Interventional
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)
  • Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Description

Subjects will undergo Excimer treatment twice a week until they reach a PASI 75 improvement, or until they reach the maximum of 20 total treatments. A blood draw to assess serum inflammatory markers will be performed at the screening visit and final visit. Chromameter assessment, photographs, PASI a...

Subjects will undergo Excimer treatment twice a week until they reach a PASI 75 improvement, or until they reach the maximum of 20 total treatments. A blood draw to assess serum inflammatory markers will be performed at the screening visit and final visit. Chromameter assessment, photographs, PASI and PGA (Physician Global Assessment) will be performed throughout the study to monitor psoriasis improvement, hyperpigmentation and erythema.

Inclusion Criterias

Age 18 years and older
Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic agents, etc) for at least 4 weeks
Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks
...
Age 18 years and older
Has been off systemic psoriasis therapies (e.g. retinoids, methotrexate, biologic agents, etc) for at least 4 weeks
Has been off topical therapies (e.g. calcipotriene, topical steroids) for at least 2 weeks
Male or female with diagnosis of psoriasis
Fitzpatrick Skin Types I-VI
Psoriasis involvement of 5-15% BSA

Exclusion Criterias

Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
Any suspicion that the psoriasis is of the photosensitive variant.
Any medical condition that could be aggravated or may cause extreme discomfort during the study period.
Active history of photosensitivity (e.g. xeroderma pigmentosum, lupus erythematosus, porphyria, severe polymorphous light eruption, solar urticaria)
Any suspicion that the psoriasis is of the photosensitive variant.
Any medical condition that could be aggravated or may cause extreme discomfort during the study period.

Locations

Concord, Ohio, 44077
Concord, Ohio, 44077

Tracking Information

NCT #
NCT02165657
Collaborators
Photomedex
Investigators
  • Principal Investigator: Margaret Bobonich, NP University Hospitals Cleveland Medical Center
  • Margaret Bobonich, NP University Hospitals Cleveland Medical Center